Newer Anti-HIV Drugs Safest, Most Effective During Pregnancy
3-11-2020Cross-posted from NIAID NewsroomDolutegravir-containing regimen exhibited superior safety profile in large, NIH-supported study of pregnant women.The antiretrov…
National Institutes of Health
NIH Study Finds Lower Concentration of PrEP Drug in Pregnant Young Women
3-9-2020Cross-posted from NIAID NewsroomAmong African adolescent girls and young women who took HIV pre-exposure prophylaxis (PrEP) daily, levels of the PrEP drug tenof…
Superior AIDS-Kaposi’s Sarcoma Treatment Improves Outcomes in Resource-Limited Settings
3-9-2020Cross-posted from NIAID NewsroomThe cancer drug paclitaxel and a suppressive regimen of antiretroviral therapy (ART) is an effective treatment for AIDS-related …
Drug-Delivery Technology Leads to Sustained HIV Antibody Production in NIH Study
3-9-2020Cross-posted from NIAID NewsroomA new approach to direct the body to make a specific antibody against HIV led to sustained production of that antibody for more …
Watch Next Week: HIV Research Updates from CROI 2020
3-4-2020HIV.gov will bring you live interviews on the latest developments in HIV research from CROI next week with NIH’s Dr. Carl Dieffenbach.
Less Than a Quarter of At-Risk Adolescent Boys Ever Get Tested for HIV
2-25-2020Cross-posted from National Institutes of HealthLess than one in four adolescent men who have sex with men (AMSM) ever get tested for HIV, research funded by the…
Youth with HIV Less Likely Than Adults to Achieve Viral Suppression
2-25-2020Cross-posted from National Institutes of HealthDespite similar rates of enrollment into medical care, youth with HIV have much lower rates of viral suppression …
NIH-Funded Clinical Trial to Test PrEP, Dapivirine Ring for Safety in Pregnant Women
2-13-2020Cross-posted from NIAID NewsroomThe first clinical trial specifically designed to test the safety of the monthly dapivirine vaginal ring in pregnant women has …
Experimental HIV Vaccine Regimen Ineffective in Preventing HIV
2-3-2020NIAID has stopped administration of investigational vaccinations in its HVTN 702 clinical trial taking place in South Africa.
NIAID Launches First Clinical Trial to Test Antibody–Drug Combination for Long-Acting HIV Treatment
1-22-2020Cross-posted from NIAID NewsroomThe first clinical trial to test the combination of a long-acting anti-HIV drug plus a powerful HIV antibody as a long-acting tr…